Similar articles

• Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus.

  Eriksson J, Nakazato M, Miyazato M, Shiomi K, Matsukura S, Groop L. Eriksson J, et al. Diabetologia. 1992 Mar;35(3):291-3. doi: 10.1007/BF00400933. Diabetologia. 1992. PMID: 1563587
• Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes.

  Ludvik B, Lell B, Hartter E, Schnack C, Prager R. Ludvik B, et al. Diabetes. 1991 Dec;40(12):1615-9. doi: 10.2337/diab.40.12.1615. Diabetes. 1991. PMID: 1756902
• Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients.

  Sanke T, Hanabusa T, Nakano Y, Oki C, Okai K, Nishimura S, Kondo M, Nanjo K. Sanke T, et al. Diabetologia. 1991 Feb;34(2):129-32. doi: 10.1007/BF00500385. Diabetologia. 1991. PMID: 2065848
• Possible links between amylin and diabetes. Amylin is released into the blood stream along with insulin.

  Luskey KL. Luskey KL. Diabetes Care. 1992 Feb;15(2):297-9. doi: 10.2337/diacare.15.2.297. Diabetes Care. 1992. PMID: 1547690 Review. No abstract available.
• [Islet amyloid polypeptide (IAPP)].

  Sanke T. Sanke T. Nihon Rinsho. 2005 Aug;63 Suppl 8:545-7. Nihon Rinsho. 2005. PMID: 16149573 Review. Japanese. No abstract available.